Drug Trial Radar · NCT05844423
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
802
Actual
Start
Mar 29, 2023
Primary completion
Aug 25, 2025
Study completion Aug 25, 2025
Sponsor
- Lead sponsor
- Vaxcyte, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 42 days, up to 89 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.
Conditions
- Pneumococcal Vaccines
Interventions
0.5 ml dose of 1.1 mcg VAX-24Biological
24 valent pneumococcal conjugate vaccine
0.5 ml dose of PCV20Biological
20 valent pneumococcal conjugate vaccine
0.5 ml dose of 2.2 mcg VAX-24Biological
24 valent pneumococcal conjugate vaccine
0.5 ml dose of 2.2/4.4 mcg VAX-24Biological
24 valent pneumococcal conjugate vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with any solicited local injection site Adverse Events (AE) within 7 days after each vaccinationTime frame: 7 days after each vaccination
- Percentage of participants with any solicited systemic AE within 7 days after each vaccinationTime frame: 7 days after each vaccination
- Percentage of participants with any related Serious Adverse Events (SAE) within 6 months after last vaccinationTime frame: 6 months after last vaccination
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
The Children's Clinic of Jonesboro, P.A.
Jonesboro, Arkansas
Madera Family Medical Group
Madera, California
Jedidiah Clinical Research
Tampa, Florida
Kentucky Pediatric/ Adult Research
Bardstown, Kentucky
ACC Pediatric Research
Haughton, Louisiana
Meridian Clinical Research
Hastings, Nebraska
Midwest Children's Health Research Institute
Lincoln, Nebraska
Midwest Children's Health Research Institute
Lincoln, Nebraska
Midwest Children's Health Research Institute
Lincoln, Nebraska
Midwest Children's Health Research Institute
Lincoln, Nebraska
Ohio Pediatric Research Assn.
Dayton, Ohio
UPMC Bass Wolfson Cranberry
Cranberry Township, Pennsylvania
Allegheny Health and Wellness Pavilion
Erie, Pennsylvania
UPMC Children's Community Pediatrics South Hills-Jefferson Hills
Jefferson Hills, Pennsylvania
UPMC Primary Care Center Oakland
Pittsburgh, Pennsylvania
UPMC Children's Community Pediatrics Bass Wolfson-Squirrel Hill
Pittsburgh, Pennsylvania
UPMC Children's Community Pediatrics-Castle Shannon
Pittsburgh, Pennsylvania
Palmetto Pediatrics, PA
North Charleston, South Carolina
Tribe Clinical Research at Parkside Pediatrics
Simpsonville, South Carolina
Coastal Pediatric Research
Summerville, South Carolina
Holston Medical Group
Kingsport, Tennessee
Ventavia Research Group
Burleson, Texas
Ventavia
Houston, Texas
Kool Kids Pediatrics
Houston, Texas
Pediatric Associates
Houston, Texas
Pediatric Center
Richmond, Texas
Alliance for Multispecialty Research
Layton, Utah
Alliance for Multispecialty Research
Murray, Utah
Alliance for Multispecialty Research
Provo, Utah
Alliance for Multispecialty Research
Roy, Utah
Alliance for Multispecialty Research
Syracuse, Utah
Pediatric Research of Charlottesville, LLC
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.